Last reviewed · How we verify
NCT04202510
IOP and Medication Reduction in MIGS Procedures
NA trial testing Glaucoma and Cataract Surgery in Open Angle Glaucoma. Withdrawn.
12 November 2020
Quick facts
| Lead sponsor | Wills Eye |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Start date | 6 January 2020 |
| Primary completion | 12 November 2020 |
| Estimated completion | 12 November 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Glaucoma and Cataract Surgery
Conditions studied
- Open Angle Glaucoma — all drugs for Open Angle Glaucoma →
- Primary Open Angle Glaucoma — all drugs for Primary Open Angle Glaucoma →
- Pigmentary Glaucoma — all drugs for Pigmentary Glaucoma →
- Pseudoexfoliation Glaucoma in Both Eyes — all drugs for Pseudoexfoliation Glaucoma in Both Eyes →
Sponsor
Wills Eye — full company profile →
Who can join
40 and older, any sex, with Open Angle Glaucoma or Primary Open Angle Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this research is to compare the efficacy of trabecular minimally invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular pressure (IOP) and anti-glaucoma medication reduction in open angle glaucoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04202510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Open Angle Glaucoma
Currently open trials in the same condition.
- NCT07228221 — Standalone iStent Infinite and iDose TR for Management of Moderate to Severe Open Angle Glaucoma · Phase 4 · recruiting
- NCT06883123 — Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost · Phase 4 · recruiting
- NCT06666855 — A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China · Phase 3 · active not recruiting
- NCT06246136 — Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery · NA · recruiting
- NCT06061718 — Travoprost Intraocular Implant in Conjunction With Cataract Surgery · Phase 3 · active not recruiting
Other Wills Eye trials
Trials by the same sponsor.
- NCT05660447 — A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR · Phase 2, PHASE3 · active not recruiting
- NCT05325996 — Evaluating Home Testing Devices for the Management of Glaucoma · NA · completed
- NCT06130384 — Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection. · Phase 4 · completed
- NCT04784234 — Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin · NA · terminated
- NCT04459949 — Comparative Study of Sharkskin Versus Grieshaber Forceps During ILM Peeling · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04202510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wills Eye
- Last refreshed: 21 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04202510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing